1Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Eur Heart J,2007,28(12) :1462 - 1536.
2Karagiannis A ,Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism [ J ]. Expert Opin Pharmacother,2008,9 ( 4 ) :509 - 515.
3Weir RA, Mark PB, Petrie C J, et al. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? [ J ]. Am Heart J,2009,157 (6) : 1088 - 1096.
4Solomon SD, Appelbaum E, Manning WJ,et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan,or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy [ J ]. Circulation, 2009, 119 ( 4 ) : 530 - 537.
5Tran LT, MacLeod KM, McNeill JH. Endothelin-1 modulates angiotensin Ⅱ in the development of hypertension in fructose-fed rats [J]. Mol Cell Biochem,2009,325( 1 -2) :89 -97.
6Zlatkovic J, Arrell DK, Kane GC, et al. Proteomic profiling of KATP channel-deficient hypertensive heart maps risk for maladaptive cardiomyopathic outcome [J]. Proteomics, 2009, 9 ( 5 ) : 1314 - 1325.
7Ball C J, Wilson DP, Turner SP, et al. Heterogeneity of L- and T- channels in the vasculature:rationale for the efficacy of combined L- and T-blockade[J].Hypertension,2009,53 (4) :654 - 660.
8Ulfhammer E,Carlstrom M, Bergh N, et al. Suppression of endothelial t-PA expression by prolonged high laminar shear stress [ J ]. Biochem Biophys Res Commun ,2009,379 ( 2 ) :532 - 536.
9Peterson SJ,Frishman WH. Targeting heme oxygenase:therapeutic implications for diseases of the cardiovascular system [ J ]. Cardiol Rev,2009,17(3) :99 -111.
